{"version":"1.0","provider_name":"Sickle Cell Disease Association of America Inc.","provider_url":"https:\/\/www.sicklecelldisease.org","author_name":"Emma Day","author_url":"https:\/\/www.sicklecelldisease.org\/author\/emma\/","title":"CMO Speaks: Gene Therapy for SCD (Part 2) - Sickle Cell Disease Association of America Inc.","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"PsF7uTJyPb\"><a href=\"https:\/\/www.sicklecelldisease.org\/2023\/10\/06\/cmo-speaks-gene-therapy-for-scd-part-2\/\">CMO Speaks: Gene Therapy for SCD (Part 2)<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.sicklecelldisease.org\/2023\/10\/06\/cmo-speaks-gene-therapy-for-scd-part-2\/embed\/#?secret=PsF7uTJyPb\" width=\"600\" height=\"338\" title=\"&#8220;CMO Speaks: Gene Therapy for SCD (Part 2)&#8221; &#8212; Sickle Cell Disease Association of America Inc.\" data-secret=\"PsF7uTJyPb\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"Welcome to CMO Speaks, a blog featuring the voices of SCDAA\u2019s clinical leadership team. This is part two of a three-part series on gene therapy for sickle cell disease. Part two was written by Dr. Lewis Hsu. What comes up for you when you hear the words \u201cgene therapy?\u201d If it makes you feel overwhelmed, [&hellip;]","thumbnail_url":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2022\/12\/H-3475-CMO-Blog-Masthead_FINAL_300ppi-scaled.jpg"}